The study analyzes 1,066 publications on stereotactic ablative radiotherapy (SABR) for oligometastases from the Web of Science and PubMed databases between January 1, 2006 and December 31, 2025. Oligometastases are an intermediate stage of metastatic cancer where SABR is used as a highly precise local therapy to improve patient outcomes. Research in this area has grown significantly and consistently since 2006. The leading countries are the USA, Italy and Canada, the most productive institution is Humanitas University and the key author is Marta Scorsetti. Influential papers published in leading oncology journals, keywords highlight cancer types, metastatic sites, treatment strategies, integration of immunotherapy and artificial intelligence. Clinical studies such as SABR-COMET and ORIOLE are cited above. The study highlights the rapid development, international collaboration and research directions with translational potential of SABR.